Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pediatric Adverse Event Analysis By FDA Will Project Incidence Rates

Executive Summary

FDA plans to use hospital use data to project use among the in-patient pediatric population to determine incidence rates for adverse event reports mandated by the Best Pharmaceuticals for Children Act

You may also be interested in...



Zyrtec Mix-Ups With Zantac Cited In FDA Pediatric Adverse Events Review

FDA is working on steps to minimize medication errors for Pfizer's Zyrtec due to confusion with GlaxoSmithKline's Zantac

Zyrtec Mix-Ups With Zantac Cited In FDA Pediatric Adverse Events Review

FDA is working on steps to minimize medication errors for Pfizer's Zyrtec due to confusion with GlaxoSmithKline's Zantac

Lipitor, Zocor Pediatric Safety Surveillance Needs More Time, FDA Cmte. Says

Pediatric safety surveillance for Pfizer's Zoloft and Lipitor should continue for another year, the Anti-Infective Drugs Pediatric Advisory Subcommittee advised FDA during a June 12 meeting

Related Content

UsernamePublicRestriction

Register

LL035386

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel